Mucosal human papillomaviruses (HPVs) are the causative agents of a number of human pathologies, including benign condylomas, as well as of the majority of cervical cancers and their high-grade precursor lesions. Although the viral E6 protein is known to be essential for driving malignant progression of HPV-infected cells, there are still many uncertainties about its mode of action. In this study, we have analysed the intracellular distribution of the E6 oncoproteins from the high-risk HPV-18 and the low-risk HPV-11. We show that both E6 proteins localize within the nucleus in nuclear bodies that are confocal with the promyelocytic leukaemia (PML) protein. Using a panel of different PML isoforms, we demonstrate specific co-localization between the E6 proteins and PML isoforms I-IV, but not with PML isoforms V and VI. We also demonstrate the interaction between E6 and a subset of PML isoforms in vivo. As a consequence of this interaction, the insoluble form of PML IV is destabilized by HPV-18 E6 through a proteasome-dependent pathway. Interestingly, both HPV-11 E6 and HPV-18 E6 can readily overcome PML IV-induced cellular senescence in primary cells. These results show separable functions for different PML isoforms that are specifically targeted by the HPV E6 oncoproteins.
Introduction
HPVs are species-specific double-stranded DNA viruses that infect squamous epithelial cells of the skin and the anogenital, laryngeal and pulmonary mucosa. According to the site of the infection and the type of lesion caused, they are classified into cutaneous and mucosal, and low-risk and high-risk, respectively, the latter being associated with cervical cancer, non-melanoma skin cancer and head and neck cancer (zur Hausen, 1987 (zur Hausen, , 2000 . Most HPV-positive high-grade lesions harbour integrated partial HPV genomes with the sustained expression of E6 and E7, both of which have oncogenic activities in a variety of cell transformation assays (Kanda et al., 1988; Vousden et al., 1988; Bedell et al., 1989; Sedman et al., 1991) . One of their most important features is the ability to cooperate in the immortalization of primary cervical keratinocytes (Barbosa and Schlegel, 1989; Munger et al., 1989) . The alterations in growth and differentiation of the cells in these in vitro systems also appear to reflect the progressive oncogenic processes that result in carcinoma in vivo (DiPaolo et al., 1986; Durst et al., 1987) . The retention and continued expression of the two viral oncoproteins is essential for maintenance of the transformed phenotype, as demonstrated by the fact that they are retained over time (Schwarz et al., 1985; Androphy et al., 1987; Banks et al., 1987) and that inhibition of their expression results in apoptosis or senescence of HPV-positive cancer cells (von Knebel Doeberitz et al., 1992; Alvarez-Salas et al., 1998; Butz et al., 2000; Goodwin et al., 2000; Wells et al., 2000; Jiang and Milner, 2002) .
Although numerous cellular targets have been described for the HPV oncoproteins (reviewed in Mantovani and Banks, 2001; Munger et al., 2001) , recent studies suggest that certain HPV E6 proteins can accumulate within nuclear bodies and exhibit confocality with PML (Guccione et al., 2002) . These nuclear bodies, also known as PML oncogenic domains (PODs), are implicated in the pathophysiology of acute promyelocytic leukaemia (APL) (Alcalay et al., 1992; Chen and Chen, 1992) . These nuclear sub-compartments are dynamic structures, of which the PML protein is the major regulator, controlling POD organization and function (Dyck et al., 1994; Lallemand-Breitenbach et al., 2001) . The PML gene comprises nine exons that are alternatively spliced and which give rise to at least seven isoforms. All these isoforms differ within their Cterminal regions, and all of them, with the exception of isoform VII, localize in discrete domains within the nucleus (Jensen et al., 2001) .PML has multiple domains (Jensen et al., 2001 ) and can be modified by the small ubiquitin-like protein SUMO-1, at lysines 65, 160 and 490 (Kamitani et al., 1998; Duprez et al., 1999) . This modification would appear to be essential for correct formation of PODs (Zhong et al., 2000; LallemandBreitenbach et al., 2001) . Interestingly, PML SUMOylation has been the only SUMO-1 modification found to be essential for POD targeting. Other proteins shown to be modified by SUMO-1 at the specific CKXE consensus (Rodriguez et al., 2001) and to interact with PML, such as p53, Daxx, SP100 and CBP/p300 continue to localize to PODs even in the absence of this modification (Sternsdorf et al., 1997; Gostissa et al., 1999; Jang et al., 2002) . Since recent studies have shown that PODs, and in particular those containing PML isoform IV, may play a role in apoptosis and senescence (Pearson et al., 2000; Pearson and Pelicci, 2001 ), we were interested in investigating further the biological significance of E6 accumulation within POD structures. In this study, we demonstrate the association between the HPV E6 oncoprotein and a subset of PML isoforms, suggesting that E6 targets specific and different functions of PML. The biological relevance of this interaction is highlighted by the demonstration that E6 can overcome PML IV-induced senescence of primary epithelial cells, and this therefore provides one explanation as to how HPV can overcome cellular senescence, and hence contribute towards malignant transformation.
Results

HPV-18 E6 and HPV-11 E6 localize in discrete nuclear domains
Previous studies have shown that the low-risk HPV-11 E6 protein is localized mainly in the nucleus and is confocal with the cellular proteins PML and SUMO-1, while the high-risk HPV-18 E6 protein generates a more diffuse pattern of expression (Guccione et al., 2002) . However, interpretation of these studies has been complicated by the fact that any construct expressing HPV-18 E6 also expresses the alternatively spliced E6*I (Pim et al., 1997) . In order to study the localization of the full-length HPV-18 E6 protein, we generated an E6 mutated at the splice donor site, thereby generating a construct that will only produce the full-length HPV-18 E6 protein (HA-18 E6 NS). This construct was tested for its functionality and found to be able to induce degradation of p53 in vivo (data not shown) similarly to that reported for the non-splicing mutant form of HPV-16 E6 (Sedman et al., 1991) . We then proceeded to compare the pattern of expression of the full-length HPV-18 E6 and the HPV-11 E6 proteins. U2-OS and CaSKi cells were transfected with the respective HAtagged constructs and after 24 h cells were fixed, and stained with anti-HA antibody. The results obtained are shown in Figure 1 . As can be seen, while full-length HPV-18 E6 also has some weak cytoplasmic localization, there is a very high proportion of nuclear punctuate staining, similar to that seen with HPV-11 E6. Since we had previously found that these HPV-11 E6 nuclear dots were confocal with PML, we also costained both assays with anti-PML antibodies. As can be seen from Figure 1 , both HPV-11 E6 and HPV-18 E6 proteins co-localize with endogenous PML. Identical results were also obtained when the assays were performed in other epithelial cell lines, HeLa and HaCaT (data not shown).
HPV-11 E6 and HPV-18 E6 are confocal with PML isoforms I-IV Previous studies have shown that there is extensive alternative splicing of the PML gene, resulting in at least seven different isoforms (Jensen et al., 2001) . Although the function of these different isoforms is unknown, many studies have reported isoform-specific protein interactions (Alcalay et al., 1998; Fogal et al., 2000; Li et al., 2000; Wu et al., 2001) , suggesting that not all forms are functionally equivalent. Therefore, we were particularly interested in determining whether the HPV-11 and HPV-18 E6 proteins were being targeted to any specific subset of PML isoforms. In order to do this, we made use of a panel of FLAG-tagged PML isoforms that are depicted schematically in Figure 2a , and performed co-transfection experiments into U2-OS cells with the HA-tagged HPV E6 proteins and the FLAGtagged PML isoforms. After 24 h, the cells were fixed and stained for both sets of proteins. The results for HPV-11 E6 are shown in Figure 2b and the results for HPV-18 E6 are shown in Figure 3a . As can be seen, HPV-11 E6 shows a very high degree of confocality with PML isoforms I-IV. In contrast, there is no significant degree of co-localization with PML isoforms V and VI. Interestingly, the distribution of these latter two forms ranges from complete exclusion to an adjacent distribution in different cells. Similarly, HPV-18 E6 shows a very high degree of confocality with PML isoforms I-IV, but not with isoforms V and VI. In order to exclude artifacts due to the use of the FLAG antibody, we also repeated the experiment, but stained the cells with an anti-PML antibody (PG-M3) that recognizes both endogenous and overexpressed PML. The results for HPV-18 E6 and the different PML isoforms are shown in Figure 3b . As can be seen, the results are comparable with those obtained using the anti-FLAG antibody. Therefore, these results demonstrate that the localization of E6 to PODs is highly specific in that only a subset of these structures is being targeted. In addition, it also shows that the particular PODs to which the two different E6 proteins are being targeted are also similar, suggesting a highly conserved function of the low-and high-risk HPV E6 oncoproteins.
DAXX does not mediate E6 targeting to specific PML isoforms
Recent reports indicate that the POD component DAXX is one of the possible driving forces for viral protein accumulation into PODs (Ishov et al., 2002; Becker et al., 2003) . To investigate if DAXX was similarly recruiting the E6 proteins to PODs, we analysed the co-localization of DAXX with PML isoforms IV and VI in the presence or absence of 18E6. U2-OS cells were transfected with a pCDNA3-DAXX expression construct in combination with the different FLAG-PML isoforms, and immunofluorescence staining was performed as previously described. DAXX was found to co-localize with both PML isoforms IV and VI (Figure 4a-f) but, importantly, when 18E6 was also co-transfected, DAXX retained its confocality with PML VI, while E6 did not. These results demonstrate that DAXX and E6 co-localize with different PML isoforms, suggesting that E6 is not being recruited to POD structures via DAXX.
Interaction of the HPV E6 proteins with specific PML isoforms
Having shown that the HPV E6 proteins are targeted to PML isoform-specific PODs, we were then interested in determining whether the E6 proteins were interacting with the respective PML proteins. In order to do this, in vitro translated 35 S-labelled-PML isoforms were incubated with GST-11 E6 and GST-18 E6 fusion proteins, as well as with GST alone as a negative control. The beads were then washed, and subjected to SDS-PAGE, and the results of the autoradiograph are shown in Figure 5a . As can be seen, interaction was detected between the E6 proteins and PML isoforms I, II and IV, but not with isoforms III, V or VI, nor with the GST-negative control. Interestingly, both 11 E6 and 18 E6 bound the PML isoforms with approximately equal affinity. A Coomassie staining of the gel shows equal input of the GST proteins ( Figure 5a lower panel).
Next, we wanted to assess if the interaction between E6 and the different PML isoforms was also occurring in vivo. U2-OS cells were transfected with the HA-tagged E6 together with the FLAG-tagged PML isoforms. After 24 h, the proteins were extracted and immunoprecipitated either with anti-FLAG antibody ( Figure 5b ) or with anti-HA antibody ( Figure 5c ). The immunoprecipitates were then analysed by Western blotting for the presence of the HA-tagged E6 proteins and FLAGtagged PML proteins, and the results obtained are Interaction between E6 and PML E Guccione et al shown in Figure 5 , panels B and C. As can be seen, there is strong interaction between the HPV-11 E6 protein and a subset of PML isoforms. The strongest interaction would appear to be between HPV-11 E6 and isoforms II and IV, with a weaker binding to isoforms I and V. The highly specific nature of these interactions is highlighted by the lack of interaction between HPV-11 E6 and isoforms III and VI. The level of interaction obtained between the HPV-18 E6 protein and the different PML isoforms is much less; nonetheless a weak interaction is visible with isoforms II and IV. These results therefore demonstrate substantial differences between the two viral oncoproteins in how they associate with the different PML-specific PODs in vivo.
Since both the co-immunoprecipitation and the immunofluorescence experiments were carried out in a PML-positive background, we also wanted to assess the localization of the HPV-11 E6 and 18 E6 proteins in a PML null background. In order to do this, PML null mouse fibroblasts were transfected with HPV-11 and HPV-18 E6, together with the different PML isoforms. To our great surprise, both HPV-11 E6 and HPV-18 E6 retained a punctuate pattern of expression even in the absence of PML (data not shown). However, as can be seen from Figure 6 , both E6 proteins show no colocalization with PML isoforms III, V and VI. Taken together, these results are in agreement with the coimmunoprecipitation analysis, and suggest that the co-localization of E6 with isoform III (Figure 2 ) is most likely a reflection of the presence of other PML isoforms.
HPV-18 E6 targets a subset of PML IV for proteolytic degradation
We were somewhat surprised by the differences in protein interaction profiles between HPV-11 and HPV-18 E6 that we observed in vivo. However, previous studies have shown that the HPV-18 E6 oncoprotein can target many of its substrates for proteasome-mediated degradation (Mantovani and Banks, 2001) , which frequently makes detection of HPV-18 E6-bound proteins extremely difficult. To investigate this possibility further, we proceeded to investigate the effects of HPV-11 and HPV-18 E6 upon the steady-state levels of PML IV. We also used PML VI as a negative control since this isoform showed no binding to the HPV-11 E6. Cells were transfected with the HA-tagged E6 proteins together with the FLAG-tagged PML isoforms. After 24 h, the cells were treated for 2 h with the proteasome inhibitor CBZ in order to rescue any proteins that were being degraded at the proteasome. Cells were then extracted and the protein fractions were divided into soluble and insoluble fractions, and the presence of the PML protein was detected by Western blotting. The results obtained are shown in Figure 7 . As can be seen, 
Interaction between E6 and PML E Guccione et al HPV-18 E6 induces a dramatic decrease in the quantity of the insoluble form of PML isoform IV, and this is rescued by treatment with CBZ, suggesting that it is being actively degraded at the proteasome. Interestingly, HPV-18 E6 had no effect upon the levels of expression of the soluble form of PML IV nor on the PML isoform VI, suggesting that its ability to target a subset of PML IV protein for degradation is highly specific. In contrast, HPV-11 E6 appears to have no effect on the steady-state levels of any of the PML isoforms.
HPV E6 proteins inhibit the ability of PML IV to induce cellular senescence PML IV has been recently shown to display a specific ability to induce cellular senescence in primary fibroblasts, while the other PML isoforms do not exert such activity (Alcalay et al., 1998; Fogal et al., 2000; Bischof et al., 2002) . Since previous studies have shown that blocking E6 expression in HeLa cells can result in replicative senescence (Goodwin et al., 2000; Wells et al., 2000) , we were interested in investigating whether the interaction between the HPV E6 proteins and PML IV might affect the ability of PML IV to induce senescence. In order to do this, we established an assay for inducing cellular senescence in primary Baby Rat Kidney (BRK) cells. The cells were transfected with plasmids expressing PML IV or PML VI, together with plasmids expressing HPV-11 and HPV-18 E6. The other PML isoforms were not included since previous studies have shown that they fail to induce cellular senescence (Bischof et al., 2002) . After 12 days of selection with G418, the cells were fixed Figure 8 , where it can be seen that approximately 12% of cells were senescent in the presence of PML IV, which is comparable to the levels obtained with the positive control of EJ-ras alone (Bischof et al., 2002) . In agreement with previous studies, PML VI had no effect upon the number of senescent cells. Most interestingly, however, both HPV-11 and HPV-18 E6 were both equally capable of reducing the number of PML IV-induced senescent cells to almost background levels. These results demonstrate that, although HPV-11 and HPV-18 E6 may target PML IV through different mechanisms, their net effect is the same with respect to their ability to overcome PML IV-induced cellular senescence.
Discussion
Over recent years, PML has been the subject of intense investigation and it is now clear that PODs play a central role in regulating functions involved in cell cycle control, apoptosis and cellular senescence (Alcalay et al., 1998; LaMorte et al., 1998; Torii et al., 1999; Ferbeyre et al., 2000; Fogal et al., 2000; Pearson et al., 2000) . There is also increasing evidence that alternatively spliced PML isoforms may play different roles in these diverse biological processes (Jensen et al., 2001; Bischof et al., 2002) . Indeed, recent studies provided evidence for the existence of different PODs within the cell, with dynamic compositions, suggesting possibly different functions (Muratani et al., 2002; Wiesmeijer et al., 2002) . In agreement with this concept, we have found that the HPV-11 and HPV-18 E6 proteins are targeted to defined POD structures within the nucleus, which comprise specifically PML isoforms I, II and IV, but not PML isoforms III, V and VI. These results demonstrate that these POD structures have different PML compositions and suggest that the viral E6 proteins target only a subset of those domains that are important for specific viral activities. We then proceeded to investigate whether the HPV E6 proteins could interact with the different PML isoforms both in vitro and in vivo. Interestingly, HPV-11 E6 shows a very strong interaction with PML isoforms I, II and IV, but no interaction with isoform VI, and this is consistent with the in vivo co-localization data. The results with isoforms V and III are somewhat more difficult to interpret. Isoform V shows no binding in vitro, a weak interaction with HPV-11 E6 in vivo, but no significant degree of co-localization, while isoform III exhibits strong co-localization in PML-positive cells, no co-localization in PML null cells, and does not appear to interact in any of the binding assays. The most likely explanations for these apparent discrepancies are that at this stage we cannot say which interactions are direct, and it is also likely that in the immunofluorescence analysis the isoform III containing PODs may well be recruiting other endogenous isoforms with which the E6 proteins are truly interacting. The results obtained in PMLÀ/À cells are in support of this hypothesis, since only PML isoforms I, II and IV appear to truly colocalize with the E6 proteins, while PML III does not. Due to the fact that no isoform-specific antibodies are available, it is important to also note that we have only been able to monitor E6 and specific PML isoforms under conditions of transient transfection. Taken together, however, these studies provide very strong evidence that a subset of PML proteins, defined by isoforms I, II and IV, are targets of the HPV E6 proteins.
The reduced level of HPV-18 E6 detected in the coimmunoprecipitation experiments with the different PML isoforms was somewhat surprising, considering its apparently equal propensity to bind in vitro and colocalize with a subset of PML isoform containing POD Interaction between E6 and PML E Guccione et al structures. However, since HPV-18 E6 readily targets many of its substrate proteins for degradation, we reasoned that this might be an explanation for this discrepancy. Indeed, this would seem to be the case. Coexpression of HPV-18 E6 with PML isoform IV induced a dramatic reduction in the steady-state levels of the insoluble form of the protein, which could be rescued by treating the cells with a proteasome inhibitor. Interestingly, PML VI, with which HPV-18 E6 does not co-localize in vivo, was also unaffected by the presence of the HPV-18 E6 protein. Therefore, these studies suggest that HPV-18 E6 specifically triggers the proteolytic degradation of only a portion of PML IV. Obviously, it will be of great interest to identify whether this form of PML has different activities compared with the soluble form of the protein, which is not targeted by E6. The HPV-11 E6 protein interacts with specific PML isoforms in vivo. U2-OS cells were transiently transfected with the different FLAG-tagged PML isoforms either alone or together with HPV-11E6 and HPV-18E6 expression constructs. After 24 h, the cells were harvested and the lysates were immunoprecipitated with an anti-FLAG antibody (M2). The immunocomplexes were then analysed by Western blotting with an anti-HA (3F10) antibody to detect co-immunoprecipitated HPV E6 proteins, or with an anti-FLAG (M2) antibody to detect the immunoprecipitated PML isoforms. Arrows indicate the respective proteins, while * denotes the IgG. The first two lanes on the left represent two negative controls where the E6 expression plasmids were transfected in the absence of any PML isoform. The bottom panel shows the Western blot for HA-E6 and represents 10% of the total protein used in the coimmunoprecipitation experiment. As can be seen, there is strong co-precipitation between HPV-11 E6 and PML isoforms I, II and IV. (c) PML isoforms I, II and IV interact with HPV-11 E6 in vivo. U2-OS cells were transiently transfected with the different FLAGtagged PML isoforms either alone or together with the HPV-11E6 expression construct. After 24 h, the cells were harvested and the lysates were immunoprecipitated with an anti-HA antibody (3F10). The immunocomplexes were then analysed by Western blotting with an anti-FLAG (M2) antibody to detect co-immunoprecipitated PML isoforms, or with an anti-HA (3F10) antibody to detect the immunoprecipitated E6 protein. Arrows indicate the respective proteins. The bottom panel shows the Western blot for HA-E6 and represents 10% of the total protein used in the co-immunoprecipitation experiment. As can be seen, there is co-precipitation between HPV-11 E6 and PML isoforms I, II and IV Interaction between E6 and PML E Guccione et al
The accumulation of both E6 proteins within PODs is intriguing. POD targeting by viral proteins has been found to be essential for an efficient viral life cycle in the cases of adenovirus, EBV, HSV-1 and CMV (Everett and Maul, 1994; Ahn and Hayward, 1997; Ahn et al., 1998; Everett et al., 1998; Muller and Dejean, 1999) . In all these cases, the viruses encode at least one protein that is able to target and reorganize PODs. In the case of HPV-11, we have shown that E6 and E7 both localize to PODs (Guccione et al., 2002) , as do the E1 and E2 proteins (Swindle et al., 1999) . Moreover, the L2 minor capsid protein from both HPV and BPV co-localizes with PML bodies and is able to recruit the L1 major capsid protein and the E2 into PODs (Day et al., 1998; Heino et al., 2000) . These studies point to PML nuclear domains as being central players at the later stages of viral replication and capsid assembly. This hypothesis is further supported by recent studies demonstrating that the L2 protein is also capable of inducing POD re-organization in differentiating epithelia (Florin  et al., 2002a, b) . Interestingly, L2 POD localization seems to be mediated by DAXX, and this is also true for the tegument transactivator pp71 protein of HCMV, which facilitates viral genome deposition and transcription in PODS (Ishov et al., 2002; Becker et al., 2003) . This does not seem to be the case for the 18E6 protein, whose PODs targeting is independent of DAXX.
In the case of the HPV E6 proteins, the interaction with certain PML isoforms may also have more sinister implications than just having a function during viral replication. Recent studies have shown that PML isoform IV is a potent inducer of cellular senescence (Pearson and Pelicci, 2001; Bischof et al., 2002) . Intriguingly, recent reports also showed that reducing HPV gene expression in cervical tumourderived cell lines could also result in an induction of senescence (Wells et al., 2000) . Therefore, we reasoned that these two observations may indeed be connected. In agreement with this hypothesis, we found that both the HPV-11 and the HPV-18 E6 proteins were potent inhibitors of PML IV-induced senescence in primary Interaction between E6 and PML E Guccione et al epithelial cells. Hence, while inhibiting this function of PML may be an important element for the replication of both viruses, it may also represent a key step in the process of HPV-18 E6-induced malignant transformation.
Materials and methods
Cells and transfections
U2-OS, CaSKi, PMLÀ/À fibroblasts and primary baby rat kidney cells were all grown in DMEM plus 10% heatinactivated foetal calf serum. Transfections were done by the calcium phosphate precipitation method as described previously (Wigler et al., 1979) , or by SuperFec reagent (Qiagen) as indicated by the manufacturer. For the proteasome inhibition experiments, cells were grown for 2 h in the presence of 50 mM carbobenzoxy-L-leucyl-L-leucyl-L-leucinal (CBZ) diluted in DMSO (Sigma) or DMSO alone as a negative control. Cells were plated in six-well dishes (1 Â 10 5 per plate, 0.5 mg of PML plasmids and 2.5 mg of the E6 plasmids were used in the immunoprecipitation experiments).
Plasmids HA-tagged HPV11 E6 and HPV18 E6 expression vectors have been described previously (Guccione et al., 2002) . The HAtagged HPV18 E6 construct expressing just the full-length E6 protein was obtained using the GeneTailor site-directed mutagenesis system (Invitrogen) according to the manufacturer's instructions. A G-to-C mutation was inserted at the splice donor site (position 130 from ATG) as described previously for HPV-16 E6 (Sedman et al., 1991) . FLAG-PML clones are in a pCIneo backbone, based originally around a clone for PML VI that had the cDNA inserted with NcoI and EcoRI ends into the vector SmaI site (kindly provided by R Everett). This was modified with a FLAG oligo at the N-terminus between vector EcoRI and SalI sites to give a 12-residue-N-terminal extension carrying the epitope. Different isoforms were then made by substituting-in the relevant C-terminal fragments (cDNAs kindly provided by E Solomon, PG Pelicci and A Dejean) from the SmaI site in common exon 5. The products were verified by DNA sequencing. These clones will be described more fully elsewhere (KJL, NK and KNL, manuscript in preparation). pCDNA3-DAXX was kindly provided by G Del Sal.
Immunofluorescence
At 24 h after transfection, U2-OS and CaSKi cells were fixed in 3% paraformaldehyde in PBS for 20 min at room temperature, washed once with 0.1 M glycine, permeabilized with 0.1% Triton X-100 in PBS and then incubated with the primary antibody diluted 1 : 200 for 1 h in PBS 2% BSA. FLAG-PML was detected with the M2 mouse monoclonal antibody (SIGMA) or with a mouse monoclonal antibody (PG-M3, Santa Cruz, USA). HA-tagged proteins were detected with a polyclonal rabbit antibody (Y-11, Santa Cruz, USA). DAXX was detected with a rabbit polyclonal antibody (M-112, Santa Cruz). Following five washes in PBS, the cells were incubated with a 1 : 1000 dilution of fluorescein-conjugated goat antirabbit antibody (Molecular Probes) and Rhodamine-Red conjugated goat anti-mouse antibody (Molecular Probes) for 20 min. The cells were then washed several times in water and mounted on glass slides using Vectashield mounting medium. Experiments using different secondary antibodies in dual labelling experiments or using secondary antibodies in the absence of the primary were performed to check for artifactual results.
Confocal microscopy
Slides were analysed using a Zeiss LSM 510 confocal microscope with two lasers giving excitation lines at 480 and Figure 7 The HPV-18 E6 protein targets a fraction of PML isoform IV for proteasome-mediated degradation. U2-OS cells were transiently transfected with the FLAG-tagged PML isoforms IV and VI, either alone or in combination with HA-tagged HPV-11 E6 and HPV-18 E6 proteins. After 24 h, the cells were harvested and a high salt (0.5 M NaCl) extraction was performed to extract soluble material (PML soluble), while the remainder was termed insoluble (PML insoluble). The two different fractions were then analysed for steady-state levels of the two different PML isoforms by Western blotting with an anti-FLAG antibody (M2). The proteasome inhibitor MG132 (CBZ) was added 2 h prior to harvesting ( þ ) in half of the transfections to determine whether the PML isoforms were being subjected to proteasome-mediated degradation. The upper panel shows a Western blot for anti-GFP that was used as a control for transfection efficiency. The lower panels show a Western blot for HA that was used to monitor E6 expression levels. Lanes 3 and 4 show a clear reduction in the protein levels of insoluble PML isoform IV in the presence of HPV-18 E6, which is rescued by addition of CBZ Interaction between E6 and PML E Guccione et al 510 nm. The data were collected at 1024 Â 1024 pixels resolution. The microscope was a Zeiss Axiovert 100M utilizing an Â 100 objective oil-immersion lens. The scanning conditions used were kept constant in each experiment and ensured that the signal overlap between channels was essentially eliminated.
In vitro transcription-translation and gst pull-down assays
Proteins were expressed in vitro, using TNT reticulocyte lysate system (Promega) in the presence of L-35 S-labelled cysteine (Amersham 0.6 mCi/1 ml of reaction volume) for 2 h. They were then incubated for 90 0 at room temperature with equal amounts of GST fusion proteins bound to glutathione-linked agarose beads. The reaction was carried out in a final volume of 50 ml, in a binding buffer containing 50 mM Tris-HCl (pH 7.5), 150 mM NaCl and 2.5 mM EDTA. The bound proteins were washed extensively in PBS/0.5% NP40. SDS-PAGE and autoradiography were used to analyse the pattern of bound proteins. Assays were quantitated using a phosphoimager (Instant Imager, Packard).
Immunoprecipitations and Western blotting
U2-OS cell were transfected and harvested 24 h later. Cells were washed twice in cold PBS, then scraped in high-salt buffer (25 mM HEPES (pH 7.0), 0.1%NP40, 500 mM NaCl, protease inhibitor cocktail (Calbiochem), phosphatase inhibitor and 1 mM NaButyrate). Cells were left on ice for 20 min and then sonicated for 5 s. The pellet (insoluble fraction) was separated from the soluble fraction (supernatant) following centrifugation at 13 K r.p.m.
Extracts were subjected to SDS-PAGE and Western blotting onto a 0.22 mm membrane (Schleicher and Schuell) and then incubated first with the appropriate primary antibody (overnight at 41C) in 1% milk/PBS, then washed three times in 0.2% Tween/PBS and further incubated for 1 h at RT with the peroxidase-conjugated secondary antibody. After extensive washings with 0.2% Tween/PBS, protein levels were assessed through a standard ECL reaction (Amersham) or a femto-ECL (Pierce) in the case of HA-E6.
Senescence analysis
Senescence in primary baby rat kidney cells was assessed by staining for senescence associated b-galactosidase (SA-b-Gal), as previously described (Dimri et al., 1995) . BRKs were kept under G418 selection (2.28 mg/ml) for 12 days.
